Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 35 clinical trials
Role of A2A Receptor in Hypercholesterolemic Patients

(statins, ezetimibe, PCSK9 inhibitors or LDL-apheresis) reduces the risk of major cardiovascular events in proportion to the absolute reduction of LDL-cholesterol (LDL-C). Nevertheless, a better

ezetimibe
cardiovascular disease
hypercholesterolemia
cholesterol measurement
endothelial dysfunction
  • 0 views
  • 15 Nov, 2021
  • 1 location
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management

A 400-patient U.S.-based single-center Quality Improvement Initiative in the form of a randomized controlled trial focused on the feasibility of implementation of this electronic alert-based CDS (EPIC BPA) based on LDL-C values. The 400 patients will be comprised of 200 in the "Hospitalized Patient Cohort" and 200 in the "Outpatient …

  • 0 views
  • 29 Oct, 2021
  • 1 location
A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia

This is a randomized, double-blind, placebo-controlled phase Ⅲ clinical study evaluating the efficacy and safety of AK102 in patients with primary hypercholesterolemia and mixed hyperlipidemia.

fasting
serum low density lipoprotein
ezetimibe
hypercholesterolemia
hmg-coa reductase inhibitors
  • 0 views
  • 16 Mar, 2022
  • 1 location
A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia

This is a randomized, double-blind, placebo-controlled phase # clinical study evaluating the efficacy and safety of AK102 Q6W in patients with primary hypercholesterolemia and mixed hyperlipidemia.

fasting
serum low density lipoprotein
ezetimibe
hypercholesterolemia
hmg-coa reductase inhibitors
  • 0 views
  • 06 Mar, 2022
  • 1 location
A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia

This is a randomized, double-blind, placebo-controlled phase 3 clinical study evaluating the long-term efficacy and safety of AK102 in patients with primary hypercholesterolemia and mixed hyperlipidemia.

fasting
serum low density lipoprotein
ezetimibe
hypercholesterolemia
hmg-coa reductase inhibitors
  • 0 views
  • 14 Mar, 2022
  • 1 location
Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers

Background Drinking alcohol can lead to swelling and injury in the liver. Long-term heavy drinking may lead to liver disease. Researchers want to study the relationship between a drug called alirocumab, alcohol use, and liver functioning/swelling. Objective To study the effects of alirocumab in people who drink alcohol. Eligibility Healthy …

Accepts healthy volunteers
  • 0 views
  • 22 Jul, 2022
  • 1 location
Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids

Every 3 minutes a new case of diabetes is diagnosed in Canada, mostly type 2 diabetes (T2D) increasing the risk for heart disease. T2D and heart disease share many common risk factors such as aging, obesity and unhealthy lifestyle. Paradoxically however, while lowering blood LDL, commonly known as "bad cholesterol", …

fish oil
heart disease
omega-3 fatty acids
fatty acids
hmg-coa reductase inhibitors
  • 0 views
  • 09 Sep, 2021
  • 1 location
Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia

IBI306 is a bio-innovative drug against proprotein convertase subtilisin 9 (PCSK-9) monoclonal antibody. Currently, cholesterol-lowering drugs with multiple mechanisms of action are on the market or under development. Among them, anti-PCSK-9 monoclonal antibodies have received widespread attention due to their good safety and efficacy. The results of existing preclinical studies …

  • 0 views
  • 10 Jul, 2021
  • 1 location
Ezetimibe Utilization Early After Acute Myocardial Infarction "EzAMI Trial"

Rationale Patients with acute coronary syndromes are at an increased risk for recurrent adverse coronary events, particularly during the early period following their initial presentation. Early (in-hospital) initiation of high-intensity statins reduces the risk of recurrent events and is therefore recommended by the best current practice guidelines.(1,2) However, the delayed …

combination therapy
myocardial infarction
ezetimibe
statin therapy
hmg-coa reductase inhibitors
  • 0 views
  • 06 Aug, 2021
  • 1 location
Russian Familial Hypercholesterolemia Registry (RuFH)

True prevalence of FH in the Russian Federation is unknown which leads to low percentage of diagnosed and treated cases. Research is needed to determine the prevalence of FH, specific diagnostic algorithms and optimal treatment strategies. The main aim of the present study is to evaluate the extent to which …

genetic analysis
atherosclerosis
pcsk9
low density lipoprotein
cholesterol level
  • 11 views
  • 24 Jan, 2022
  • 1 location